820993-72-4

Upstream product

• 31139-02-3 (1R,6S)-6-methoxycarbonyl-3-cyclohexene-1-carboxylic acid 
• 115-11-7 isobutene 
• 4841-84-3 dimethyl cis-1,2,3,6-tetrahydrophthalate 
• 36805-97-7 N,N-dimethylformamide di-tert-butyl acetal 

Downstream Products

• 820993-73-5 (1R,6S)-6-Azidocarbonyl-cyclohex-3-enecarboxylic acid tert-butyl ester 
• 91280-46-5 tert-butyl (1S,6S)-6-methoxycarbonylaminocyclohex-3-enecarboxylate 
• 111860-30-1 (1R,2S,5S)-5-Methanesulfonyloxy-2-(methoxycarbonyl-methyl-amino)-cyclohex-3-enecarboxylic acid methyl ester 
• 111515-78-7 methyl (1R,2S,5S)-5-hydroxy-2-cyclohex-3-enecarboxylate 
• 91259-93-7 tert-butyl (1R,6S)-6-methoxycarbonylaminocyclohex-3-enecarboxylate 
• 124287-84-9 (1R,6S)-6-<(methoxycarbonyl)amino>cyclohex-3-enecarboxylic acid 
• 124287-88-3 1-N-benzyl-1-N-(benzyloxycarbonyl)-6-O-(tert-butyldimethylsilyl)-4,5-N,O-carbonyl-3-de-O-methylfortamine 
• 111515-84-5 (1R,4S,5R,6R)-4-(N-benzyl-N-(benzyloxycarbonyl)amino)-5-<(tert-butyldimethylsilyl)oxy>-9-methyl-8-oxo-9-aza-7-oxabicyclo<4.3.0>non-2-ene 
• 124287-83-8 methyl (1R,2R,4S,5R,6R)-4-<(benzyloxycarbonyl)amino>-5-<(tert-butyldimethylsilyl)oxy>-9-methyl-8-oxo-9-aza-7-oxabicyclo<4.3.0>nonanecarboxylate 
• 111515-82-3 (1R,2R,4S,5R,6R)-4-<(benzyloxycarbonyl)amino>-5-<(tert-butyldimethylsilyl)oxy>-9-methyl-8-oxo-9-aza-7-oxabicyclo<4.3.0>nonanecarboxylic acid 
• 111515-85-6 1-N-benzyl-6-O-(tert-butyldimethylsilyl)-1,2:4,5-di-N,O-carbonylfortamine 
• 111515-83-4 (1R,4S,5R,6R)-4-<(benzyloxycarbonyl)amino>-5-<(tert-butyldimethylsilyl)oxy>-9-methyl-8-oxo-9-aza-7-oxabicyclo<4.3.0>non-2-ene 
• 111515-81-2 methyl (1R,2R,4S,5R,6R)-4-<(benzyloxycarbonyl)amino>-5-hydroxy-9-methyl-8-oxo-9-aza-7-oxabicyclo<4.3.0>nonanecarboxylate 
• 111515-86-7 1-N-benzyl-1,2:4,5-di-N,O-carbonylfortamine 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS

The present invention relates to compounds that are Nrf2 activators. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with Nrf2 activation.

Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition

A serendipitous discovery that the metalloprotease binding profile of a novel class of 2-carboxamide-3-hydroxamic acid piperidines could be significantly attenuated by the modification of the unexplored P1 substituent enabled the design and synthesis of a

Synthesis of optically active methyl 7 β-hydroxykaurenoate with potent neuroprotective activity

(-)-Methyl 7β-hydroxykaurenoate (3) and its 4-demethyl acetate (-)-4 were both synthesized via methods that contained radical cyclization and intramolecular Diels-Alder reactions as key steps. Both compounds displayed potent neuroprotective activity again

An Enantioselective Synthesis of (-)-Fortamine

The aminocyclitol moiety of fortimicin A, (-)-fortamine, was synthesized in an enantioselective manner starting from the chiral half ester, easily available by the enantioselective hydrolysis of a symmetrical diester with pig liver esterase.The present ap

CREATION OF NOVEL CHIRAL SYNTHONS WITH ENZYMES AND APPLICATIONS TO NATURAL PRODUCT SYNTHESIS. 15. EFFICIENT INTRODUCTION OF CHIRAL CENTERS INTO CYCLOHEXANE RING.

The chiral half-ester 2 obtained by asymmetric hydrolysis of the symmetric diester 1 with pig liver esterase has been shown to be a versatile synthon for various chiral cyclohexane derivatives.